The Global Next Generation Sequencing Market is estimated to be USD 9.51 Bn in 2020 and is expected to reach USD 25.28 Bn by 2025, growing at a CAGR of 21.6%.
The major factors such as increasing research and development activities utilizing the NGS technologies, growing applications of NGS in clinical diagnosis, and discovery applications demanding NGS technology are expected to drive the growth of the overall market. The rapid speed, cost, and accuracy of the NGS technology have also helped in the growth of the market. However, the current market is facing challenges due to the difficulty in the management of large data and complications associated with Big Data management.
Recent Developments 1. In September 2020, Illumina Inc. acquired GRAIL, a healthcare company focused on multi-cancer early detection, for cash and stock consideration of USD 8 billion upon closing of the transaction. 2. In August 2020, Guardant Health Inc. received the United States Food and Drug Administration (FDA) approval for Guardant360 CDx, the first liquid biopsy companion diagnostic that also uses next-generation sequencing (NGS) technology for tumor mutation profiling, also known as comprehensive genomic profiling (CGP), in patients with any solid malignant neoplasm (cancerous tumor). 3. In 2019, Qiagen launched NGS panels and liquid biopsy solutions with integrated bioinformatics to lead advances in cancer research.
Some of the companies covered in this report are 10x Genomics, 454 Life Sciences Corporation (Roche Holding AG), Agilent Technologies Inc., Beijing Genomics Institute, Bio matters Ltd., Bio-Rad Laboratories Inc., DNASTAR Inc., Eurofins Scientific, F. Hoffmann-La Roche AG, GATC Biotech AG., GenapSys Inc., Qiagen N.V., Thermo Fisher Scientific Inc., etc.
The report includes a Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.
Why buy this report?
The report offers a comprehensive evaluation of theGlobal Next Generation Sequencing Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
The report includes in-depth market analysis using Porter's 5 force model and the Ansoff Matrix. The impact of Covid-19 on the market is also featured in the report.
The report also contains the competitive analysis using the Competitive Quadrant, the analyst's proprietary competitive positioning tool.
A complete analysis of the market, including parent industry
Important market dynamics and trends
Historical, current, and projected size of the market based on value and volume
Market shares and strategies of key players
Recommendations to companies for strengthening their foothold in the market
Key Topics Covered:
1 Report Description
2 Research Methodology
3 Executive Summary
4 Market Overview 4.1 Introduction 4.2 Market Dynamics 4.2.1 Drivers 220.127.116.11 Increasing Applications in Clinical Diagnosis 18.104.22.168 Speed, Cost, and Accuracy 22.214.171.124 Efficient Replacement for Traditional Technologies (Microarrays) 126.96.36.199 Increasing need of inexpensive sequencing devices in routine medical checkups and clinical settings 4.2.2 Restraints 188.8.131.52 Standardization concerns over NGS based diagnostics 184.108.40.206 Lack of skilled professionals 220.127.116.11 Huge data processing and reimbursement uncertainty in clinical settings 4.2.3 Opportunities 18.104.22.168 Lucrative opportunities in emerging markets 22.214.171.124 Potential significance of NGS analysis in identifying cancer mutations 126.96.36.199 Investigate NGS use to enable single-cell genomics 4.2.4 Challenges 188.8.131.52 Data analysis and bioinformatics challenges 4.3 Trends
5 Market Analysis 5.1 Porter's Five Forces Analysis 5.2 Impact of COVID-19 5.3 Ansoff Matrix Analysis
6 Global Next Generation Sequencing Market, By Type 6.1 Introduction 6.2 Whole genome sequencing 6.3 Exome sequencing 6.4 Targeted sequencing 6.5 Others
7 Global Next Generation Sequencing Market, By Application 7.1 Introduction 7.2 Research application 7.3 Clinical application 7.4 Others
8 Global Next Generation Sequencing Market, By Technology 8.1 Introduction 8.2 Sequencing by synthesis 8.3 Ion semiconductor sequencing 8.4 Others
9 Global Next Generation Sequencing Market, By End User 9.1 Introduction 9.2 Academic institutes & research centres 9.3 Hospitals & clinics 9.4 Pharmaceutical & biotechnology companies 9.5 Others
10 Global Next Generation Sequencing Market, By Geography 10.1 Introduction 10.2 North America 10.2.1 US 10.2.2 Canada 10.2.3 Mexico 10.3 South America 10.3.1 Brazil 10.3.2 Argentina 10.4 Europe 10.4.1 UK 10.4.2 France 10.4.3 Germany 10.4.4 Italy 10.4.5 Spain 10.4.6 Rest of Europe 10.5 Asia-Pacific 10.5.1 China 10.5.2 Japan 10.5.3 India 10.5.4 Indonesia 10.5.5 Malaysia 10.5.6 South Korea 10.5.7 Australia 10.5.8 Russia 10.5.9 Rest of APAC 10.6 Rest of the World 10.6.1 Qatar 10.6.2 Saudi Arabia 10.6.3 South Africa 10.6.4 United Arab Emirates 10.6.5 Latin America
12 Company Profiles 12.1 10x Genomics 12.2 454 Life Sciences Corporation (Roche Holding AG) 12.3 Agilent Technologies Inc. 12.4 Beijing Genomics Institute 12.5 Bio matters Ltd. 12.6 Bio-Rad Laboratories Inc. 12.7 DNASTAR Inc. 12.8 Eurofins Scientific 12.9 F. Hoffmann-La Roche AG 12.10 GATC Biotech AG. 12.11 GenapSys Inc. 12.12 GENEWIZ 12.13 Genomatix GmbH 12.14 Illumina Inc. 12.15 Macrogen Inc. 12.16 Myriad Genetics Inc. 12.17 New England Biolabs Inc. 12.18 NuGEN Technologies Inc. 12.19 Oxford Nanopore Technologies Limited 12.20 Pacific Biosciences of California Inc. 12.21 Partek Inc. 12.22 PerkinElmer Inc. 12.23 PierianDx. 12.24 Qiagen N.V. 12.25 Thermo Fisher Scientific Inc.